Japan's Ministry of Health has approved GlaxoSmithKline's RSV vaccine, Arexvy, for individuals aged 50 to 59 at risk, expanding its use from those aged 60 and above.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
GSK gains approval in Japan for extended indication of RSV vaccine
